Cargando…

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

OBJECTIVE: Cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type 2 diabetes without use of these medications. It remains unknown whether exenatide or sitagliptin increase the risk of acute pancreatitis. RESEARCH DESIGN AND METHODS: A retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garg, Rajesh, Chen, William, Pendergrass, Merri
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963493/ https://www.ncbi.nlm.nih.gov/pubmed/20682680 http://dx.doi.org/10.2337/dc10-0482

Ejemplares similares

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
por: Tatarkiewicz, K, et al.
Publicado: (2013)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Impact of Non-Tailored One-Way Automated Short Messaging Service (OASMS) on Glycemic Control in Type 2 Diabetes: A Retrospective Feasibility Study
por: Alamer, Ahmad, et al.
Publicado: (2020)

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment
por: Buonaiuto, Giulia, et al.
Publicado: (2016)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
por: Sue, Mariko, et al.
Publicado: (2013)

Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO‐2 randomized clinical study
por: Gadde, Kishore M., et al.
Publicado: (2017)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
por: Berg, J K, et al.
Publicado: (2011)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

A student-implemented elective to improve medical student confidence in providing diabetes self-management support
por: Fazel, Maryam T, et al.
Publicado: (2016)

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Neuromodulation Induced by Sitagliptin: A New Strategy for Treating Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2021)

Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
por: Kirkman, M. Sue, et al.
Publicado: (2015)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
por: Le, Yunyi, et al.
Publicado: (2022)

Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data
por: Carroll, Cathryn A, et al.
Publicado: (2014)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Hypoglycemia and Clinical Outcomes in Patients With Diabetes Hospitalized in the General Ward
por: Turchin, Alexander, et al.
Publicado: (2009)

Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin
por: Ma, Rui, et al.
Publicado: (2022)

Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
por: Best, Jennie H., et al.
Publicado: (2011)

Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes
por: Ferreira, Mari Cassol, et al.
Publicado: (2019)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Pharmacoepidemiology resources in Ireland—an introduction to pharmacy claims data
por: Sinnott, Sarah-Jo, et al.
Publicado: (2017)

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
por: Russell-Jones, David, et al.
Publicado: (2012)

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin
por: Lima-Martínez, Marcos M, et al.
Publicado: (2014)

Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin
por: Benido Silva, Vânia, et al.
Publicado: (2023)

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
por: Engel, S S, et al.
Publicado: (2010)

Sitagliptin-induced pancreatitis – a longer road than expected
por: Nelson, Matthew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_46uqm3kvg6pkna5n0anobe6vsr